AU2002231223A1 - Compositions and methods for treating hematologic malignancies and multiple drug resistance - Google Patents
Compositions and methods for treating hematologic malignancies and multiple drug resistanceInfo
- Publication number
- AU2002231223A1 AU2002231223A1 AU2002231223A AU3122302A AU2002231223A1 AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1 AU 2002231223 A AU2002231223 A AU 2002231223A AU 3122302 A AU3122302 A AU 3122302A AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- methods
- drug resistance
- multiple drug
- hematologic malignancies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24354200P | 2000-10-26 | 2000-10-26 | |
US60/243,542 | 2000-10-26 | ||
PCT/US2001/049856 WO2002034291A2 (fr) | 2000-10-26 | 2001-10-25 | Compositions et procedes servant a traiter des malignites hematologiques et la resistance a des medicaments multiples |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002231223A1 true AU2002231223A1 (en) | 2002-05-06 |
Family
ID=22919154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002231223A Abandoned AU2002231223A1 (en) | 2000-10-26 | 2001-10-25 | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
Country Status (3)
Country | Link |
---|---|
US (1) | US7105656B2 (fr) |
AU (1) | AU2002231223A1 (fr) |
WO (1) | WO2002034291A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
SI2264172T1 (sl) | 2002-04-05 | 2017-12-29 | Roche Innovation Center Copenhagen A/S | Oligomerne spojine za modulacijo izražanja HIF-1alfa |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
AU2004207576B8 (en) * | 2003-01-28 | 2008-11-20 | Rexahn Pharmaceuticals, Inc. | Antisense oligonucleotides that inhibit expression of HIF-1 |
CA2513398C (fr) * | 2003-01-31 | 2013-09-10 | Rexahn Corporation | Oligonucleotides anti-sens inhibant l'expression du hif-1 |
FR2860237B1 (fr) | 2003-09-30 | 2006-03-10 | Centre Nat Rech Scient | Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire |
KR101176245B1 (ko) | 2004-11-09 | 2012-08-22 | 엔존 파마슈티컬즈, 인코포레이티드 | HIF-1a 발현의 억제를 위한 효능적 LNA 올리고뉴클레오티드 |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
EP2506840B1 (fr) * | 2009-12-04 | 2021-01-06 | Oncoimmune Inc. | Utilisation d'inhibiteurs du facteur induit par l'hypoxie |
WO2021247632A1 (fr) * | 2020-06-02 | 2021-12-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systèmes et méthodes de traitement du cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968735A (en) * | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US6001991A (en) * | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
EP0960126A4 (fr) | 1996-11-05 | 2004-05-19 | Univ Texas | Compositions et utilisations relatives a la sentrine, une proteine de protection contre la mort cellulaire |
EP1009753B1 (fr) | 1997-08-21 | 2005-04-20 | Quark Biotech, Inc. | Genes regules au niveau de l'hypoxemie |
US5985664A (en) | 1998-12-17 | 1999-11-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of Sentrin expression |
GB9911047D0 (en) | 1999-05-12 | 1999-07-14 | Isis Innovation | Assay method and means |
SE0002551D0 (sv) | 2000-07-06 | 2000-07-06 | Pharmacia & Upjohn Ab | Screening methods |
-
2001
- 2001-10-25 US US10/007,255 patent/US7105656B2/en not_active Expired - Fee Related
- 2001-10-25 AU AU2002231223A patent/AU2002231223A1/en not_active Abandoned
- 2001-10-25 WO PCT/US2001/049856 patent/WO2002034291A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20050203036A1 (en) | 2005-09-15 |
US7105656B2 (en) | 2006-09-12 |
WO2002034291A3 (fr) | 2003-05-30 |
WO2002034291A2 (fr) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001285143A1 (en) | Methods and compositions for targeted delivery | |
AU2002335647A1 (en) | Methods and devices for electrosurgery | |
AU2001277754A1 (en) | Proline derivatives and use thereof as drugs | |
AU2001294808A1 (en) | Catecholamine pharmaceutical compositions and methods | |
AU8547001A (en) | Composition and method for inhibiting platelet aggregation | |
AU2002230407A1 (en) | Compounds and methods for treating multidrug resistance | |
AU2001280599A1 (en) | Compounds and methods | |
HU0103078D0 (en) | Pharmaceutical compositions and methods for treating cataracts | |
AU2001253418A1 (en) | Compounds and methods | |
AU5326100A (en) | Pharmaceutical compositions and methods for use | |
AU2002359126A1 (en) | Benzodiazepine derivatives, preparation thereof and use thereof | |
AU5565099A (en) | Pharmaceutical compositions and methods for use | |
AU2002359123A1 (en) | Benzodiazepine derivatives, preparation thereof and use thereof | |
AU2002236626A1 (en) | Compositions and methods for treating hyperpigmentation | |
AU2001243394A1 (en) | Compounds and methods | |
AU2002231223A1 (en) | Compositions and methods for treating hematologic malignancies and multiple drug resistance | |
AU2002249888A1 (en) | Microbial blend compositions and methods for their use | |
IL154240A0 (en) | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | |
AU2001227084A1 (en) | N-arylhydrazide compounds and use thereof as drugs | |
PL365602A1 (en) | Pharmaceutical compositions and methods for use | |
AUPQ872300A0 (en) | Compounds and methods | |
AU2001233932A1 (en) | Method and composition | |
AU2001249409A1 (en) | Ricin inhibitors and methods for use thereof | |
IL153897A0 (en) | Pharmaceutical compositions and methods for use | |
AU2001278951A1 (en) | Compounds and methods |